The tuberculosis pandemic - Which way now?

Journal of Infection

Volumn 38, Issue 2, 1999, Pages 74-79

  Zumla, A ^a   Mwaba, P ^b   Squire, S B ^c   Grange, J M ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; CAUSE OF DEATH; COMORBIDITY; DRUG INDICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PUBLIC HEALTH; REVIEW; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0032892367     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(99)90072-5     Document Type: Review

References (41)

1. Ryan F. Tuberculosis: the Greatest Story Never Told. Bromsgrove, Worcestershire: Swift, 1992.
2. Meyers JA. Man's Greatest Victory Over Tuberculosis. Springfield, Illinois: Charles C. Thomas, 1940.
3. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Amer Rev Respir Dis 1991; 144: 745-749.
4. World Health Organization. TB - a Global Emergency. Geneva: World Health Organization. 1994 (WHO/TB/94.177).
5. Raviglione MC, Luelmo F. Update on the global epidemiology of tuberculosis. Curr Issues Publ Hlth 1996; 2: 192-197.
6. Raviglione MC, Nunn P. Epidemiology of Tuberculosis. In: Zumla A, Johnson MA, Miller RF, eds. AIDS and Respiratory Medicine. London: Chapman and Hall, 1997: 117-141.
7. Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco - a population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
8. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull Wld Hlth Org 1994; 72: 213-220.
9. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention, and cost. Bull Int Union Tuberc Lung Dis 1990; 65(1): 6-24.
10. World Health Organization. The World Health Report 1998. Geneva: World Health Organization, 1998.
11. Communicable Disease Report. Outbreak of hospital acquired multidrug resistant tuberculosis. CDR Wkly 1995; 5(34): 161.
12. Bouvet E, Casalino E, Mendoza-Sassi G et al. A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients. A case-control study. AIDS 1993; 7: 1453-1460.
13. Antonucci G, Girardi E, Raviglioni HC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. J Amer Med Assoc 1995; 274: 143-148.
14. UNAIDS. Aids Epidemic Update: December 1998. Geneva: World Health Organization, 1998.
15. Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis 1997; 1: 205-214.
16. Chum HJ, O'Brien RJ, Chonde TM et al. An epidemiological study of tuberculosis and HIV infection in Tanzania. 1991-1993. AIDS 1996; 10: 299-309.
17. Luo C, Chintu C, Bhat G et al. Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thiacetazone-free regimen. Tubercle Lung Dis 1994; 75: 110-115.
18. Goletti D, Weissman D, Jackson RW et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-8.
19. Centers for Disease Control. The 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 1993; 41-17: 1-19.
20. Lienhardt C, Rodriguez LC. Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks revisited? Int J Tuberc Lung Dis 1997; 1: 196-204.
21. Festenstein F, Grange JM. Tuberculosis and the acquired immune deficiency syndrome. J Appl Bacteriol 1991; 71: 19-30.
22. Daley CL. The typically 'atypical' radiographic presentation of tuberculosis in advanced HIV disease. Tubercle Lung Dis 1995; 76: 475-476.
23. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
24. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993; 144: 104-110.
25. Vareldzis BP, Grosset J, de Kantor I et al. Drug resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle Lung Dis 1994; 75: 1-7.
26. Collins CH, Grange JM, Yates MD. Tuberculosis Bacteriology. Organization and Practice. 2nd edn. Oxford: Butterworth-Heinemann, 1997.
27. World Health Organization. Anti-tuberculosis Drug Resistance in the World. The WHO/IUATLD Project an Anti-tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization Global Tuberculosis Programme, 1997.
28. Gordin FM, Nelson ET, Matts JP et al. The impact of human immunodeficiency virus infection on drug resistant tuberculosis. Am J Respir Crit Care Med 1996; 154: 1478-1483.
29. Anastasis D, Pillai G, Rambiritch V, Abdool Karim SS. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. Tubercle Lung Dis 1997; 1: 220-224.
30. Moore-Gillon J. Tuberculosis and Poverty in the Developed World. In: Davies PDO, ed. Clinical Tuberculosis. 2nd edition. London: Chapman and Hall, 1998: 383-393.
31. Meek J. Killer TB Threat to World. The Guardian: Sept 23, 1998: 15.
32. Cosivi O, Grange JM, Daborn CJ et al. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis 1998; 4: 59-70.
33. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s? Wld Hlth Forum 1997; 18: 225-247.
34. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112.842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
35. Chowdhury AMR, Chowdhury S, Islam MN, Islam A, Vaughan JP. Control of tuberculosis by community health workers in Bangladesh. Lancet 1997; 350: 169-172.
36. Garner P. What makes DOTS work? Lancet 1998; 352: 1326-1327.
37. Pronyk P, Porter JDH. Public health and human rights: the ethics of international public health interventions for tuberculosis. In: Grange JM, Porter JDH, eds. Tuberculosis - an Interdisciplinary Perspective. London: Imperial College Press, 1999: 99-120.
38. Farmer P, Bayona J, Becerra M et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
39. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. Br Med J 1998; 317: 625-629.
40. O'Brien RJ. Preventive therapy. In: Davies PDO, ed. Clinical Tuberculosis, 2nd edition. London: Chapman and Hall, 1998: 397-416.
41. Young DB. Blueprint of the white plague. Nature 1998; 393: 537-544.